Literature DB >> 19043645

Rapid cognitive decline in Alzheimer's disease. Consensus paper.

M E Soto1, S Andrieu, C Arbus, M Ceccaldi, P Couratier, T Dantoine, J-F Dartigues, S Gillette-Guyonnet, F Nourhashemi, P-J Ousset, M Poncet, F Portet, J Touchon, B Vellas.   

Abstract

The rate of cognitive decline in Alzheimer's disease (AD) varies considerably between individuals, with some subjects showing substantial deterioration and others showing little or no change over the course of the disease. These wide variations support the relatively new concept of Rapid Cognitive Decline (RCD). Patients with an accelerated rate of cognitive decline have showed to present a worse evolution in terms of mortality, loss of autonomy and institutionalisation. The conclusions from RCD studies conducted in the past years remain very heterogeneous and sometimes contradictory. This is possibly due to methodological differences, mainly the different "a priori" definitions of RCD used to identify rapid decliners. Consequently of this, there is considerable variation in reported frequency of patients with RCD which may vary from 9.5% to 54%. The lack of both consensus definition and consensual clinical assessment tools is one of the major barriers for establishing an appropriated management of rapid decliners in clinical practice. Presently, management of rapid decliners in AD remains to be a challenge waiting to better know predictive factors of a RCD. To date no specific guidelines exist to follow-up or to treat patients with this condition. This consensus paper proposes the loss of 3 points or greater in Mini-Mental State Examination (MMSE) during six months as an empirical definition of rapid cognitive decline to be used in routine medical practice and to be relevant for clinical-decision making in patients with mild to moderately-severe AD.

Entities:  

Mesh:

Year:  2008        PMID: 19043645     DOI: 10.1007/bf03028618

Source DB:  PubMed          Journal:  J Nutr Health Aging        ISSN: 1279-7707            Impact factor:   4.075


  68 in total

1.  Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies.

Authors:  Kaarin J Anstey; Chwee von Sanden; Agus Salim; Richard O'Kearney
Journal:  Am J Epidemiol       Date:  2007-06-14       Impact factor: 4.897

Review 2.  Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease.

Authors:  Roger M Lane; Martin R Farlow
Journal:  J Lipid Res       Date:  2005-02-16       Impact factor: 5.922

3.  Rate of progression of cognitive decline in Alzheimer's disease: effect of butyrylcholinesterase K gene variation.

Authors:  C Holmes; C Ballard; D Lehmann; A David Smith; H Beaumont; I N Day; M Nadeem Khan; S Lovestone; M McCulley; C M Morris; D G Munoz; K O'Brien; C Russ; T Del Ser; D Warden
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-05       Impact factor: 10.154

4.  Investigation of profile difference between Alzheimer's disease patients declining at different rates: examination of baseline neuropsychological data.

Authors:  Timothy B Atchison; Major Bradshaw; Paul J Massman
Journal:  Arch Clin Neuropsychol       Date:  2004-12       Impact factor: 2.813

5.  Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both.

Authors:  M L Kraybill; E B Larson; D W Tsuang; L Teri; W C McCormick; J D Bowen; W A Kukull; J B Leverenz; M M Cherrier
Journal:  Neurology       Date:  2005-06-28       Impact factor: 9.910

6.  Cognitive decline in Alzheimer disease: Impact of spirituality, religiosity, and QOL.

Authors:  Yakir Kaufman; David Anaki; Malcolm Binns; Morris Freedman
Journal:  Neurology       Date:  2007-05-01       Impact factor: 9.910

7.  Cognitive decline in patients with Alzheimer disease: differences in patients with and without extrapyramidal signs.

Authors:  T P Miller; J R Tinklenberg; J O Brooks; J A Yesavage
Journal:  Alzheimer Dis Assoc Disord       Date:  1991       Impact factor: 2.703

8.  Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease.

Authors:  Joseph J Locascio; Hiroaki Fukumoto; Liang Yap; Teodoro Bottiglieri; John H Growdon; Bradley T Hyman; Michael C Irizarry
Journal:  Arch Neurol       Date:  2008-06

9.  The rate of cognitive decline and risk of reaching clinical milestones in Alzheimer disease.

Authors:  Roee Holtzer; Domonick J Wegesin; Steven M Albert; Karen Marder; Karen Bell; Marilyn Albert; Jason Brandt; Yaakov Stern
Journal:  Arch Neurol       Date:  2003-08

10.  Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.

Authors:  David Wilkinson; Henning Friis Andersen
Journal:  Dement Geriatr Cogn Disord       Date:  2007-07-04       Impact factor: 2.959

View more
  17 in total

1.  Behavioral management in the person with dementia.

Authors:  J E Morley
Journal:  J Nutr Health Aging       Date:  2013-01       Impact factor: 4.075

2.  Is AD a homogeneous nosologic entity? Yes.

Authors:  P Martinez-Martin
Journal:  J Neural Transm (Vienna)       Date:  2013-07-05       Impact factor: 3.575

3.  Cerebrospinal fluid β-amyloid 1-42 correlates with rate of progression in Alzheimer's disease.

Authors:  George S Vlachos; George P Paraskevas; Dimitris Naoumis; Elizabeth Kapaki
Journal:  J Neural Transm (Vienna)       Date:  2012-03-30       Impact factor: 3.575

4.  Diagnosis of Alzheimer's disease patients with rapid cognitive decline in clinical practice: interest of the Deco questionnaire.

Authors:  L Carcaillon; G Berrut; F Sellal; J F Dartigues; S Gillette; J J Pere; I Bourdeix
Journal:  J Nutr Health Aging       Date:  2011-05       Impact factor: 4.075

5.  Predictive Factors of Rapid Cognitive Decline in Patients with Alzheimer Disease.

Authors:  Coralie Barbe; Isabella Morrone; J L Novella; Moustapha Dramé; Aurore Wolak-Thierry; Jean-Pierre Aquino; Joël Ankri; Damien Jolly; Rachid Mahmoudi
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2016-12-05

6.  Disease Progression in Mild Dementia due to Alzheimer Disease in an 18-Month Observational Study (GERAS): The Impact on Costs and Caregiver Outcomes.

Authors:  Roy W Jones; Jeremie Lebrec; Kristin Kahle-Wrobleski; Grazia Dell'Agnello; Giuseppe Bruno; Bruno Vellas; Josep M Argimon; Richard Dodel; Josep Maria Haro; Anders Wimo; Catherine Reed
Journal:  Dement Geriatr Cogn Dis Extra       Date:  2017-03-20

7.  The Progression of Alzheimer's Disease: Are Fast Decliners Really Fast? A Four-Year Follow-Up.

Authors:  Federica Barocco; Marco Spallazzi; Letizia Concari; Simona Gardini; Annalisa Pelosi; Paolo Caffarra
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

8.  Stereotactic brain injection of human umbilical cord blood mesenchymal stem cells in patients with Alzheimer's disease dementia: A phase 1 clinical trial.

Authors:  Hee Jin Kim; Sang Won Seo; Jong Wook Chang; Jung Il Lee; Chi Hun Kim; Juhee Chin; Soo Jin Choi; Hunki Kwon; Hyuk Jin Yun; Jong Min Lee; Sung Tae Kim; Yearn Seong Choe; Kyung-Han Lee; Duk L Na
Journal:  Alzheimers Dement (N Y)       Date:  2015-07-26

9.  Core cerebrospinal fluid biomarker profile in anti-LGI1 encephalitis.

Authors:  Isabelle Quadrio; Virginie Desestret; Pierre Lardeux; Anthony Fourier; Elise Peter; Aline Dorey; Sergio Muñiz-Castrillo; Alberto Vogrig; Géraldine Picard; Véronique Rogemond; Mathieu Verdurand; Maité Formaglio; Bastien Joubert; Caroline Froment Tilikete; Jérôme Honnorat
Journal:  J Neurol       Date:  2021-06-08       Impact factor: 4.849

10.  General cognitive impairment as a risk factor for motor vehicle collision involvement: a prospective population-based study.

Authors:  Carrie Huisingh; Cynthia Owsley; Virginia G Wadley; Emily B Levitan; Marguerite R Irvin; Paul MacLennan; Gerald McGwin
Journal:  Geriatrics (Basel)       Date:  2018-03-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.